Vaccine Stability Improvements Sought By GSK, Sanofi And Gates Foundation
This article was originally published in PharmAsia News
GSK’s malaria vaccine candidate is lead candidate in effort to solve the cold-chain storage problem.
You may also be interested in...
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.
Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.
Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.